Modality
Cell Therapy
MOA
JAK1i
Target
TIM-3
Pathway
RAS/MAPK
Ovarian CaPTSDSMA
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
Aug 2022
→ Feb 2025
Phase 1Current
NCT06486976
1,219 pts·PTSD
2022-08→2025-02·Active
1,219 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-021.2y agoInterim· PTSD
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025
P1
Active
Catalysts
Interim
2025-02-02 · 1.2y ago
PTSD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06486976 | Phase 1 | PTSD | Active | 1219 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |